A survey of economists (including me).
ECONOMY
-
AGI Utility Token Launch by AGI.Eth
By
–
Artificial General Intelligence Utility Token $AGI by AGI.Eth #AGIToken
-
Why User Touchpoints Matter as AI Commoditizes
By
–
Why give away the user touchpoint/surfacearea?! If everything else becomes a commodity this is the only thing you want to keep. What am i missing here?
-
AI replacing teachers: o1 model and billion-dollar investments
By
–
【 Ｌ’ＩＡ， ｕｎ ｂｏｎ ｍａîｔｒｅ ？】
L’initiative d’un collège anglais, qui va remplacer les profs par une IA, risque de faire parler. o1, le nouveau modèle d’#OpenAIdécoiffe-t-il ? 35 milliards de dollars levés en 6 mois pour l’IA #GoogleDeepMind apprend à -
AI Model Drives Unexpected Interest Among Financial Professionals
By
–
Ha, will report back. Shared with bankers, consultants, lawyers, science researchers, and accountants. And compared to previous models, it felt like accountants had the biggest shift from “I don’t really care” to “wait, can you test it on XYZ?”
-
ChatGPT-o1 impacts accountants more than other professionals
By
–
Of all the professionals that I've showed ChatGPT-o1 to yesterday and today, the one that seems to care the most is accountants.
-
China’s Technology Market Decline: Chart Analysis and Implications
By
–
Thanks. That makes a lot of sense – although I’ve heard friends and colleagues talk about the drop off happening in China for a while, the steepness of this chart seemed plausibly large
-
IDH-Mutation Pill Breakthrough: $480K Annual Cost Challenge
By
–
There's never been a successful Rx mutation-directed pill approved for brain cancer (gliomas and astrocytomas, grade 2) that extends progression-free survival, until the one directed vs IDH mutations came along. Unfortunately, its price is $480K/year https://
statnews.com/2024/09/13/vor
anigo-servier-brain-cancer-breakthrough/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9DWCCc1Ks1m4ePfKrA9eh5KuIbxXyRQ6Z8kJbcMA1R_X2AF0P3L8-bZ_ZErbz7UnVirnkrwg4a01d4C2k1RSYLVARWlg&_hsmi=324444687&utm_content=324444687&utm_source=hs_email
… -
Biopharma Competition for Rare Cardiac Amyloidosis Treatment Market
By
–
Biopharma's focus on rare conditions and financial reward, exemplified:
A rare disease—primary AATR cardiac amyloidosis—is the subject of an emerging 3-way treatment competition for many $ billions per year. https://
wsj.com/health/pharma/
the-brawl-taking-shape-over-pfizers-multibillion-dollar-heart-monopoly-43a220c2?mod=Searchresults_pos1&page=1
… @pfizer @BridgeBioPharma @Alnylam
